Pharmacogenomic Study for Individual Response to CPT-11 in Colorectal Cancer Patients (Step 2)

ABSTRACT: Interventions: Intravenous adminstration of CPT-11 100 mg/m2 on Days 1, 8, and 15, every 4 weeks Primary outcome(s): 1)Tumor response rate 2)Genotype-phenotype association (CYP3A4,CES1,2, UGT1A1, ABCG2, ABCB1, and ABCC1,2 vs toxicity), mutation -phenotype association (TOP1A, ABCG2 vs tumor response), and expression-phenotype association (TOP1A, ABCG2 vs tumor response) Study Design: Single arm Non-randomized

DISEASE(S): Stage Iv Colorectal Cancer After Palliative Operation

PROVIDER: 2609520 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR